FDA approves MixJect system for Trelstar
MixJect, a drug delivery system, has been approved for use with Watson's Trelstar Depot and Trelstar LA (triptorelin pamoate injectable suspension). MixJect features a smaller 21-gauge needle, reconstitution without the use of a needle, and a shield covering the needle both before and after drug administration to encourage compliance with occupational safety and health administration (OSHA) regulations.
Trelstar, a luteinizing hormone releasing hormone (LHRH) agonist, is indicated as a palliative treatment for advanced prostate cancer.
For more information call (866) 755-3315 or visit www.trelstar.com.